File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3810/pgm.2011.11.2496
- Scopus: eid_2-s2.0-82155192798
- PMID: 22104455
- WOS: WOS:000303420000006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: Combination therapy and adiponectin
Title | Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: Combination therapy and adiponectin |
---|---|
Authors | |
Keywords | Adiponectin Amlodipine Atorvastatin Blood pressure Endothelial function |
Issue Date | 2011 |
Publisher | JTE Multimedia, LLC. The Journal's web site is located at http://www.postgradmed.com/ |
Citation | Postgraduate Medicine, 2011, v. 123 n. 6, p. 66-71 How to Cite? |
Abstract | Background: In many countries, combination therapy with amlodipine and atorvastatin is indicated for the treatment of patients with hypertension and hypercholesterolemia. The aim of this study was to investigate the impact of this combination therapy on plasma adiponectin levels. Hypothesis: Combination therapy with amlodipine and atorvastatin would increase plasma adiponectin levels. Methods: A total of 25 patients with coronary artery disease and concomitant hypertension and hypercholesterolemia were evaluated. The combination of amlodipine and atorvastatin in 8 different dosage strengths were flexibly titrated over a period of 14 weeks. Lipid profile and plasma adiponectin were measured. Brachial flow-mediated dilation (FMD) was determined by vascular ultrasound. Results: As compared with baseline, combination therapy with amlodipine and atorvastatin signifi cantly reduced systolic and diastolic blood pressure, total cholesterol, and low-density lipoprotein cholesterol (all P < 0.05). Furthermore, there were signifi cant increases in adiponectin levels (mean [95% confidence interval (CI)], 12.1 [10.7-13.7] vs 8.1 [6.5-10.0] μg/mL; P < 0.001) and brachial FMD (4.4 ± 0.6% vs 5.6 ± 0.5%; P = 0.046) over 14 weeks of treatment. The change in adiponectin levels correlated significantly with the changes in diastolic blood pressure (r = -0.49; P = 0.014) and FMD (r = 0.55; P = 0.007). Conclusion: The results of this study indicate that along with its antihypertensive and cholesterol-lowering effects, combination therapy with amlodipine and atorvastatin appears to increase plasma adiponectin levels and improve endothelial function. © Postgraduate Medicine. |
Persistent Identifier | http://hdl.handle.net/10722/163423 |
ISSN | 2023 Impact Factor: 2.6 2023 SCImago Journal Rankings: 0.773 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, M | en_US |
dc.contributor.author | Xu, A | en_US |
dc.contributor.author | Lam, KSL | en_US |
dc.contributor.author | Cheung, BMY | en_US |
dc.contributor.author | Tse, HF | en_US |
dc.date.accessioned | 2012-09-05T05:31:12Z | - |
dc.date.available | 2012-09-05T05:31:12Z | - |
dc.date.issued | 2011 | en_US |
dc.identifier.citation | Postgraduate Medicine, 2011, v. 123 n. 6, p. 66-71 | en_US |
dc.identifier.issn | 0032-5481 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163423 | - |
dc.description.abstract | Background: In many countries, combination therapy with amlodipine and atorvastatin is indicated for the treatment of patients with hypertension and hypercholesterolemia. The aim of this study was to investigate the impact of this combination therapy on plasma adiponectin levels. Hypothesis: Combination therapy with amlodipine and atorvastatin would increase plasma adiponectin levels. Methods: A total of 25 patients with coronary artery disease and concomitant hypertension and hypercholesterolemia were evaluated. The combination of amlodipine and atorvastatin in 8 different dosage strengths were flexibly titrated over a period of 14 weeks. Lipid profile and plasma adiponectin were measured. Brachial flow-mediated dilation (FMD) was determined by vascular ultrasound. Results: As compared with baseline, combination therapy with amlodipine and atorvastatin signifi cantly reduced systolic and diastolic blood pressure, total cholesterol, and low-density lipoprotein cholesterol (all P < 0.05). Furthermore, there were signifi cant increases in adiponectin levels (mean [95% confidence interval (CI)], 12.1 [10.7-13.7] vs 8.1 [6.5-10.0] μg/mL; P < 0.001) and brachial FMD (4.4 ± 0.6% vs 5.6 ± 0.5%; P = 0.046) over 14 weeks of treatment. The change in adiponectin levels correlated significantly with the changes in diastolic blood pressure (r = -0.49; P = 0.014) and FMD (r = 0.55; P = 0.007). Conclusion: The results of this study indicate that along with its antihypertensive and cholesterol-lowering effects, combination therapy with amlodipine and atorvastatin appears to increase plasma adiponectin levels and improve endothelial function. © Postgraduate Medicine. | en_US |
dc.language | eng | en_US |
dc.publisher | JTE Multimedia, LLC. The Journal's web site is located at http://www.postgradmed.com/ | - |
dc.relation.ispartof | Postgraduate Medicine | en_US |
dc.subject | Adiponectin | - |
dc.subject | Amlodipine | - |
dc.subject | Atorvastatin | - |
dc.subject | Blood pressure | - |
dc.subject | Endothelial function | - |
dc.subject.mesh | Adiponectin - Blood | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Aged, 80 And Over | en_US |
dc.subject.mesh | Amlodipine - Pharmacology - Therapeutic Use | en_US |
dc.subject.mesh | Anticholesteremic Agents - Pharmacology - Therapeutic Use | en_US |
dc.subject.mesh | Antihypertensive Agents - Pharmacology - Therapeutic Use | en_US |
dc.subject.mesh | Biological Markers - Blood | en_US |
dc.subject.mesh | Blood Pressure - Drug Effects | en_US |
dc.subject.mesh | Brachial Artery - Physiology - Ultrasonography | en_US |
dc.subject.mesh | Cholesterol - Blood | en_US |
dc.subject.mesh | Coronary Artery Disease - Blood - Complications - Drug Therapy | en_US |
dc.subject.mesh | Dose-Response Relationship, Drug | en_US |
dc.subject.mesh | Drug Combinations | en_US |
dc.subject.mesh | Drug Therapy, Combination | en_US |
dc.subject.mesh | Endothelium, Vascular - Drug Effects - Physiology | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Heptanoic Acids - Pharmacology - Therapeutic Use | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Hypertension - Blood - Complications - Drug Therapy | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Pyrroles - Pharmacology - Therapeutic Use | en_US |
dc.subject.mesh | Triglycerides - Blood | en_US |
dc.title | Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: Combination therapy and adiponectin | en_US |
dc.type | Article | en_US |
dc.identifier.email | Xu, A:amxu@hkucc.hku.hk | en_US |
dc.identifier.email | Lam, KSL:ksllam@hku.hk | en_US |
dc.identifier.email | Cheung, BMY:mycheung@hku.hk | en_US |
dc.identifier.email | Tse, HF:hftse@hkucc.hku.hk | en_US |
dc.identifier.authority | Xu, A=rp00485 | en_US |
dc.identifier.authority | Lam, KSL=rp00343 | en_US |
dc.identifier.authority | Cheung, BMY=rp01321 | en_US |
dc.identifier.authority | Tse, HF=rp00428 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.3810/pgm.2011.11.2496 | en_US |
dc.identifier.pmid | 22104455 | - |
dc.identifier.scopus | eid_2-s2.0-82155192798 | en_US |
dc.identifier.hkuros | 205185 | - |
dc.identifier.hkuros | 213327 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-82155192798&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 123 | en_US |
dc.identifier.issue | 6 | en_US |
dc.identifier.spage | 66 | en_US |
dc.identifier.epage | 71 | en_US |
dc.identifier.isi | WOS:000303420000006 | - |
dc.publisher.place | United States | - |
dc.identifier.scopusauthorid | Li, M=26661782700 | en_US |
dc.identifier.scopusauthorid | Xu, A=7202655409 | en_US |
dc.identifier.scopusauthorid | Lam, KSL=8082870600 | en_US |
dc.identifier.scopusauthorid | Cheung, BMY=7103294806 | en_US |
dc.identifier.scopusauthorid | Tse, HF=7006070805 | en_US |
dc.identifier.issnl | 0032-5481 | - |